{"date":"2026-04-20","count":16,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6649-2026-04-20-1855-134g2u8","company_id":"6649","company":"台生材","market":"上櫃","industry":"生技醫療","date":"2026-04-20","time":"18:55:36","subject":"公告本公司115年第一季財務報告董事會召開日期","clause":"第31款","fact_date":"2026-04-20","cite_as":"公開資訊觀測站重大訊息：台生材（6649），2026-04-20 18:55，「公告本公司115年第一季財務報告董事會召開日期」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6589-2026-04-20-1815-hjaat4","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2026-04-20","time":"18:15:33","subject":"本公司受邀參加玉山證券舉辦之法人說明會","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2026-04-20 18:15，「本公司受邀參加玉山證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7803-2026-04-20-1756-w7bayx","company_id":"7803","company":"雲象科技-創","market":"上市","industry":"生技醫療","date":"2026-04-20","time":"17:56:38","subject":"公告本公司股票初次創新版上市前現金增資委託代收及存儲專戶行庫","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：雲象科技-創（7803），2026-04-20 17:56，「公告本公司股票初次創新版上市前現金增資委託代收及存儲專戶行庫」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6810-2026-04-20-1728-5sggiz","company_id":"6810","company":"新穎生醫","market":"興櫃","industry":"生技醫療","date":"2026-04-20","time":"17:28:28","subject":"本公司受邀參加第一金證券舉辦之法人說明會","clause":"第30款","fact_date":"2026-04-22","cite_as":"公開資訊觀測站重大訊息：新穎生醫（6810），2026-04-20 17:28，「本公司受邀參加第一金證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4195-2026-04-20-1721-qkrt5g","company_id":"4195","company":"基米-創","market":"上市","industry":"生技醫療","date":"2026-04-20","time":"17:21:07","subject":"公告本公司股務代理機構名稱、辦公處所及聯絡電話","clause":"第44款","fact_date":"2026-04-20","cite_as":"公開資訊觀測站重大訊息：基米-創（4195），2026-04-20 17:21，「公告本公司股務代理機構名稱、辦公處所及聯絡電話」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4195-2026-04-20-1717-bit7t7","company_id":"4195","company":"基米-創","market":"上市","industry":"生技醫療","date":"2026-04-20","time":"17:17:11","subject":"本公司股票初次上市前現金增資發行新股暨暫定承銷價相關事宜","clause":"第44款","fact_date":"2026-04-20","cite_as":"公開資訊觀測站重大訊息：基米-創（4195），2026-04-20 17:17，「本公司股票初次上市前現金增資發行新股暨暫定承銷價相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4166-2026-04-20-1716-11b1948","company_id":"4166","company":"友霖","market":"上櫃","industry":"生技醫療","date":"2026-04-20","time":"17:16:38","subject":"公告本公司董事會決議召開115年股東常會相關事宜","clause":"第17款","fact_date":"2026-02-25","cite_as":"公開資訊觀測站重大訊息：友霖（4166），2026-04-20 17:16，「公告本公司董事會決議召開115年股東常會相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2026-04-20-1711-1ipb99s","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2026-04-20","time":"17:11:02","subject":"本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之第二個多國多中心樞紐三期臨床試驗CBL-0302申請，今日已完成美國FDA送件","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2026-04-20 17:11，「本公司新藥CBL-514注射劑用於減少腹部皮下脂肪之第二個多國多中心樞紐三期臨床試驗CBL-0302申請，今日已完成美國」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4147-2026-04-20-1646-hk2f6k","company_id":"4147","company":"中裕","market":"上櫃","industry":"生技醫療","date":"2026-04-20","time":"16:46:36","subject":"公告本公司買回庫藏股執行完畢","clause":"第35款","fact_date":"2026-04-20","cite_as":"公開資訊觀測站重大訊息：中裕（4147），2026-04-20 16:46，「公告本公司買回庫藏股執行完畢」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7729-2026-04-20-1646-1aq7iqo","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2026-04-20","time":"16:46:34","subject":"本公司受邀參加元大證券舉辦之法人說明會","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2026-04-20 16:46，「本公司受邀參加元大證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7729-2026-04-20-1646-82bbnn","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2026-04-20","time":"16:46:01","subject":"公告本公司115年第一次現金增資基準日暨相關事宜(補充代收股款及存儲專戶行庫)(更正主旨年度)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2026-04-20 16:46，「公告本公司115年第一次現金增資基準日暨相關事宜(補充代收股款及存儲專戶行庫)(更正主旨年度)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1783-2026-04-20-1605-v23fae","company_id":"1783","company":"和康生","market":"上市","industry":"生技醫療","date":"2026-04-20","time":"16:05:12","subject":"公告本公司2026年第1季合併財務報告董事會預計召開日期為2026年4月28日","clause":"第31款","fact_date":"2026-04-20","cite_as":"公開資訊觀測站重大訊息：和康生（1783），2026-04-20 16:05，「公告本公司2026年第1季合併財務報告董事會預計召開日期為2026年4月28日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3184-2026-04-20-1546-15yhvdj","company_id":"3184","company":"微邦","market":"興櫃","industry":"生技醫療","date":"2026-04-20","time":"15:46:19","subject":"公告本公司法人董事改派法人代表人","clause":"第6款","fact_date":"2026-04-20","cite_as":"公開資訊觀測站重大訊息：微邦（3184），2026-04-20 15:46，「公告本公司法人董事改派法人代表人」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7607-2026-04-20-1539-3n6l6a","company_id":"7607","company":"通用幹細胞*","market":"興櫃","industry":"生技醫療","date":"2026-04-20","time":"15:39:38","subject":"公告本公司獲某醫學中心人體試驗倫理委員會(IRB)通知本公司申請「以PCP注射治療膝關節患者(PCP-KOA)」之計畫已審查通過","clause":"第44款","fact_date":"2026-04-16","cite_as":"公開資訊觀測站重大訊息：通用幹細胞*（7607），2026-04-20 15:39，「公告本公司獲某醫學中心人體試驗倫理委員會(IRB)通知本公司申請「以PCP注射治療膝關節患者(PCP-KOA)」之計畫已」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6543-2026-04-20-1537-oe90k0","company_id":"6543","company":"普惠醫工","market":"興櫃","industry":"生技醫療","date":"2026-04-20","time":"15:37:44","subject":"公告本公司董事長決議調整一一五年第一次現金增資發行價格事宜","clause":"第9款","fact_date":"2026-04-20","cite_as":"公開資訊觀測站重大訊息：普惠醫工（6543），2026-04-20 15:37，「公告本公司董事長決議調整一一五年第一次現金增資發行價格事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7814-2026-04-20-1505-13qhlmq","company_id":"7814","company":"海昌生技","market":"上櫃","industry":"生技醫療","date":"2026-04-20","time":"15:05:43","subject":"更正本公司114年第4季IFRSs iXBRL公告資訊，更正之申報資訊對本公司營業利益及稅(前)後淨利並無影響。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：海昌生技（7814），2026-04-20 15:05，「更正本公司114年第4季IFRSs iXBRL公告資訊，更正之申報資訊對本公司營業利益及稅(前)後淨利並無影響。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}